Nature Outlook 

Hepatitis B

Every year, more than 800,000 people worldwide die from hepatitis-B-related liver disease — a greater toll than from malaria. But efforts to curb transmission and discover a cure are picking up steam.

Illustration showing a lady looking into a microscope surrounded by a large stethoscope and liver

This Nature Outlook is editorially independent, produced with financial support from a third party. About this content.

Nature is pleased to acknowledge the financial support of Janssen Pharmaceutical Companies of Johnson & Johnson and Vir Biotechnology, Inc in producing this Outlook. The sponsors retains the sole responsibility for the following messages.


Janssen logoPeople living with Chronic Hepatitis B are burdened by stigma, a progressive liver disease and the potential need for a lifelong daily anti-viral treatment. The need for new treatment options is high. At Janssen, we aim for a future where hepatitis B will be a thing of the past. With a proven track record of delivering effective medicines to combat infectious diseases, we are relentless in our pursuit to develop treatments that ease the burden faced by those living with chronic hepatitis B. Through our diverse scientific approach, we aim to deliver a functional cure* to patients with chronic hepatitis B and to improve health outcomes for the millions of people living with the condition. Learn more at Follow us at @JanssenGlobal. *Note: A functional cure for chronic hepatitis B is defined as a loss of viral markers (hepatitis B surface antigen (HBsAg) and hepatitis B viral DNA) that is sustained after cessation of treatment.

Read sponsor feature


VIR logoAbout Vir Biotechnology
Vir Biotechnology is a commercial-stage company focused on combining immunologic insights with cutting-edge technologies to treat and prevent the world’s most serious infectious diseases. The Company has assembled four technology platforms designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus (HBV), influenza A and human immunodeficiency virus.

Vir’s current broad approach to HBV therapy is aimed at achieving a functional cure. By testing multiple product candidate combinations simultaneously, we hope to speed the path to a functional cure with the goal of both dramatically increasing cure rates and reducing treatment times for the more than 290 million patients around the world living with chronic HBV.

Read sponsor feature